The first under-the-skin, long-acting risperidone injection offers a new maintenance option for adults with bipolar 1 ...

The FDA has approved Uzedy (risperidone) as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.

FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I ...

Lupin has received approval from the Food and Drug Administration for risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial and 50 mg per vial, single-dose vials.

Paris: The FDA has approved UZEDY, the first subcutaneous long-acting risperidone formulation utilizing SteadyTeq™ technology ...

The RISE study 7 was a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of risperidone extended-release injectable suspension for subcutaneous use as a ...

Risperdal Consta Dosage and Administration Adult Risperidone-naive: rule out risperidone hypersensitivity before using injection. Give by deep deltoid or gluteal IM inj; alternate sides. Give with ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a long-acting subcutaneous risperidone injection for the treatment of schizophrenia in adults.

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ...

NAPLES, Fla., Sept. 10, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval ...

Lupin’s shares rose 2.8% in afternoon trading after the company received a key U.S. Food and Drug Administration (FDA) approval. On Wednesday, Lupin received USFDA approval for its Abbreviated New ...

The potentially devastating consequences of a relapse in patients with schizophrenia and the substantial risk of relapse associated with even partial compliance with therapy have made compliance a ...